REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of REGENXBIO in a report released on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar expects that the biotechnology company will post earnings of ($1.49) per share for the quarter. The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO's FY2026 earnings at ($2.03) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.47 EPS.
Other equities research analysts also recently issued research reports about the company. Raymond James assumed coverage on REGENXBIO in a research report on Friday, February 7th. They set an "outperform" rating and a $27.00 price target for the company. The Goldman Sachs Group cut their target price on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. HC Wainwright cut their price objective on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Finally, Leerink Partners set a $24.00 price target on REGENXBIO in a report on Tuesday, March 18th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, REGENXBIO presently has an average rating of "Moderate Buy" and an average target price of $31.63.
Read Our Latest Analysis on RGNX
REGENXBIO Price Performance
NASDAQ:RGNX traded up $1.01 during mid-day trading on Friday, reaching $8.83. The company's stock had a trading volume of 1,022,749 shares, compared to its average volume of 809,839. REGENXBIO has a twelve month low of $5.04 and a twelve month high of $17.52. The company's fifty day simple moving average is $6.81 and its two-hundred day simple moving average is $8.11. The stock has a market cap of $442.53 million, a P/E ratio of -1.76 and a beta of 1.26.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million.
Institutional Investors Weigh In On REGENXBIO
Several large investors have recently made changes to their positions in RGNX. FMR LLC lifted its stake in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,656 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in REGENXBIO by 9.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock worth $185,000 after purchasing an additional 1,982 shares during the period. Teacher Retirement System of Texas grew its position in REGENXBIO by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock worth $97,000 after purchasing an additional 2,088 shares in the last quarter. DnB Asset Management AS raised its stake in REGENXBIO by 20.1% during the 4th quarter. DnB Asset Management AS now owns 14,539 shares of the biotechnology company's stock valued at $112,000 after purchasing an additional 2,434 shares during the period. Finally, GAMMA Investing LLC raised its stake in REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 2,510 shares during the period. Institutional investors and hedge funds own 88.08% of the company's stock.
About REGENXBIO
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Articles
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
